SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novartis AG (NVS) trades at a trailing P/E of 20.9, forward P/E of 17.6. Trailing earnings yield is 4.79%, forward earnings yield 5.70%. PEG 0.93 (Peter Lynch undervalued ≤1.0). Graham Number is $63.29.
Criteria proven by this page:
- VALUE (40/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 17.6 (down from trailing 20.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.93 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.79% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.70% as earnings recover.
- Analyst consensus target $127.00 (-17.2% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 68/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
40/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVS
Valuation Multiples
P/E (TTM)20.9
Forward P/E17.6
PEG Ratio0.93
Forward PEG0.81
P/B Ratio6.34
P/S Ratio5.18
EV/EBITDA13.9
Per Share Data
EPS (TTM)$7.32
Forward EPS (Est.)$8.74
Book Value / Share$24.32
Revenue / Share$29.41
FCF / Share$8.76
Yields & Fair Value
Earnings Yield4.79%
Forward Earnings Yield5.70%
Dividend Yield1.99%
Graham Number$63.29
SharesGrow IV$297.22 (+93.8%)
Analyst Target$127.00 (-17.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
21.6 |
-0.35 |
1.94 |
2.93 |
4.47% |
| 2017 |
21.4 |
1.31 |
2.22 |
3.80 |
3.94% |
| 2018 |
13.2 |
0.20 |
2.12 |
3.61 |
4.18% |
| 2019 |
17.5 |
-0.41 |
3.70 |
4.22 |
3.24% |
| 2020 |
25.2 |
1.87 |
3.60 |
4.08 |
3.43% |
| 2021 |
7.7 |
0.04 |
2.74 |
4.22 |
3.97% |
| 2022 |
26.9 |
-0.38 |
3.16 |
4.31 |
4.01% |
| 2023 |
14.1 |
0.11 |
4.49 |
4.50 |
3.46% |
| 2024 |
16.4 |
-0.96 |
4.46 |
3.80 |
3.88% |
| 2025 |
19.0 |
0.85 |
5.79 |
4.88 |
2.94% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.80 |
$49.44B |
$6.71B |
13.6% |
| 2017 |
$3.25 |
$50.14B |
$7.7B |
15.4% |
| 2018 |
$5.38 |
$53.17B |
$12.61B |
23.7% |
| 2019 |
$3.08 |
$48.68B |
$7.15B |
14.7% |
| 2020 |
$3.52 |
$49.9B |
$8.07B |
16.2% |
| 2021 |
$10.63 |
$52.88B |
$24.02B |
45.4% |
| 2022 |
$3.17 |
$51.83B |
$6.96B |
13.4% |
| 2023 |
$7.10 |
$46.66B |
$14.85B |
31.8% |
| 2024 |
$5.87 |
$51.72B |
$11.94B |
23.1% |
| 2025 |
$7.19 |
$54.81B |
$14.06B |
25.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$8.77 |
$8.46 – $9.40 |
$57.58B |
$56.43B – $58.72B |
7 |
| 2027 |
$9.65 |
$9.28 – $10.11 |
$60.71B |
$58.18B – $62.6B |
7 |
| 2028 |
$10.63 |
$10.21 – $11.09 |
$64.04B |
$62.03B – $66.32B |
5 |
| 2029 |
$11.47 |
$11.01 – $11.96 |
$66.79B |
$64.69B – $69.16B |
2 |
| 2030 |
$12.55 |
$12.05 – $13.09 |
$69.56B |
$67.38B – $72.03B |
5 |
